Impact of Resveratrol and Pharmaceutical Care on Type 2 Diabetes Mellitus and Its Neuropathic Complication: A Randomized Placebo Controlled Clinical Trial

Table 2

Quantitative distribution of pharmaceutical care intervention in the Resv + PC group.

Components of PC	Subcategories in Resv + PC	n (%) subcategories	n (%) components of PC
Medication review for identification of DTPs	Indication	27 (14.13)	65 (34.03)
	Effectiveness	22 (11.51)
	Safety	9 (4.71)
	Compliance	7 (3.66)
Patient education and counseling	Counseling regarding OHA	24 (12.56)	108 (56.54)
	Counseling regarding insulin administration	11 (5.75)
	Counseling regarding hypoglycemic complications	24 (12.56)
	Counseling regarding self-blood glucose monitoring	24 (12.56)
	Counseling regarding foot care	25 (13.08)
Partnership with other health professionals	Referral to specialist nurse	3 (1.57)	18 (9.42)
	Communicate with physicians	13 (6.80)
	Referral to medical advice	2 (1.04)
Total		191 (100)	191 (100)

Values are expressed as numbers and percentages (n (%)). DTP, drug therapy problem; PC, pharmaceutical care; Resv, resveratrol; and OHA, oral hypoglycemic agent.